LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Suletud

Sektor Tervishoid

0.72 -2.7

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.71

Max

0.73

Põhinäitajad
By Trading Economics
Müük	-7.4M 2M
Aktsiakasum	-0.34
Töötajad	405

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+281.94 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-2.3M 114M
Eelmine avamishind	3.42
Eelmine sulgemishind	0.72

Uudiste sentiment

By Acuity

50%

321 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.722 / 0.81 Toetus ja vastupanu

Sangamo Therapeutics Inc Graafik

Seotud uudised

7. sept 2024, 09:30 UTC

Peamised uudised

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- WSJ

7. sept 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6. sept 2024, 21:18 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6. sept 2024, 21:05 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6. sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 20:39 UTC

Tulu

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6. sept 2024, 20:35 UTC

Peamised uudised

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6. sept 2024, 20:34 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6. sept 2024, 20:11 UTC

Peamised uudised

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6. sept 2024, 19:51 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6. sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6. sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6. sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6. sept 2024, 18:27 UTC

Peamised uudised

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6. sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6. sept 2024, 18:15 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6. sept 2024, 18:12 UTC

Peamised uudised

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6. sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6. sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6. sept 2024, 17:30 UTC

Peamised uudised

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6. sept 2024, 17:27 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6. sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6. sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6. sept 2024, 16:35 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6. sept 2024, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6. sept 2024, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

6. sept 2024, 16:20 UTC

Tulu

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6. sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Sangamo Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

281.94% tõus

12 kuu keskmine prognoos

Keskmine 2.75 USD 281.94%

Kõrge 5 USD

Madal 1 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Sangamo Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Sangamo Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.722 / 0.81Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

321 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

EBITDA

Ärikasum

Ettevõttest Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.